Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market sizing • Market size and forecast PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: MARKET SEGMENTATION BY DRUG CLASS • Comparison by drug class • CFTR modulators • Mucolytics • PERT • Anti-infectives • Bronchodilators • Market opportunity by drug class PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Regional comparison • CF therapeutics market in Americas • CF therapeutics market in EMEA • CF therapeutics market in APAC • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market Drivers • Market challenges PART 13: MARKET TRENDS • Strategic collaborations • Advances in technology for drug development and delivery PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie • Gilead • F. Hoffmann-La Roche • Vertex Pharmaceuticals PART 16: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Autosomal recessive pattern of inheritance in CF Exhibit 02: Effects of CF on different body parts Exhibit 03: Most common CFTR mutations Exhibit 04: Global birth prevalence of CF by 2017 Exhibit 05: Diagnosis and treatment of CF Exhibit 06: Parent market Exhibit 07: Market characteristics Exhibit 08: Market segments Exhibit 09: Market definition: Inclusions and exclusions checklist Exhibit 10: Market size Exhibit 11: Validation techniques employed for market sizing 2017 Exhibit 12: Global CF therapeutics market 2017-2022 ($ millions) Exhibit 13: Global CF therapeutics market: Year over year growth 2018-2022 (%) Exhibit 14: Five forces analysis 2017 Exhibit 15: Five forces analysis 2022 Exhibit 16: Bargaining power of buyers Exhibit 17: Bargaining power of suppliers Exhibit 18: Threat of new entrants Exhibit 19: Threat of substitutes Exhibit 20: Threat of rivalry Exhibit 21: Market condition: Five forces 2017 Exhibit 22: Global CF therapeutics market by drug class 2017-2022 (% share) Exhibit 23: Comparison by drug class Exhibit 24: Global CF therapeutics market by CFTR modulators 2017-2022 ($ millions) Exhibit 25: KALYDECO description Exhibit 26: ORKAMBI description Exhibit 27: Global CF therapeutics market by CFTR modulators: Year over year growth 2018-2022 (%) Exhibit 28: Global CF therapeutics market by mucolytics 2017-2022 ($ millions) Exhibit 29: Global CF therapeutics market by mucolytics: Year over year growth 2018-2022 (%) Exhibit 30: Global CF therapeutics market by PERT 2017-2022 ($ millions) Exhibit 31: Global CF therapeutics market by PERT: Year over year growth 2018-2022 (%) Exhibit 32: Global CF therapeutics market by anti-infectives 2017-2022 ($ millions) Exhibit 33: Global CF therapeutics market by anti-infectives: Year over year growth 2018-2022 (%) Exhibit 34: Global CF therapeutics market by bronchodilators 2017-2022 ($ millions) Exhibit 35: Global CF therapeutics market by bronchodilators: Year over year growth 2018-2022 (%) Exhibit 36: Market opportunity by drug class Exhibit 37: Customer landscape Exhibit 38: Global CF therapeutics market by region 2017-2022 (% share) Exhibit 39: Regional comparison Exhibit 40: CF therapeutics market in Americas 2017-2022 ($ millions) Exhibit 41: CF therapeutics market in Americas: Year over year growth 2018-2022 (%) Exhibit 42: Top three countries in Americas Exhibit 43: CF therapeutics market in EMEA 2017-2022 ($ millions) Exhibit 44: CF therapeutics market in EMEA: Year over year growth 2018-2022 (%) Exhibit 45: Top three countries in EMEA Exhibit 46: CF therapeutics market in APAC 2017-2022 ($ millions) Exhibit 47: CF therapeutics market in APAC: Year over year growth 2018-2022 (%) Exhibit 48: Top three countries in APAC Exhibit 49: Market opportunity Exhibit 50: Few drugs with breakthrough therapy designation for CF Exhibit 51: Few drugs with Orphan Drug Designation for CF Exhibit 52: Few CF therapeutics discontinued from development Exhibit 53: Partnerships and collaborations between companies for development of CF therapeutics Exhibit 54: Vendor landscape Exhibit 55: Landscape disruption Exhibit 56: Competitive structure analysis of global CF therapeutics market 2017 Exhibit 57: Vendors covered Exhibit 58: Vendor classification Exhibit 59: Market positioning of vendors Exhibit 60: AbbVie: Overview Exhibit 61: AbbVie: Business segments Exhibit 62: AbbVie: Organizational developments Exhibit 63: AbbVie: Geographic focus Exhibit 64: AbbVie: Segment focus Exhibit 65: AbbVie: Key offerings Exhibit 66: AbbVie: Key customers Exhibit 67: Gilead: Overview Exhibit 68: Gilead: Business segments Exhibit 69: Gilead: Organizational developments Exhibit 70: Gilead: Geographic focus Exhibit 71: Gilead: Segment focus Exhibit 72: Gilead: Key offerings Exhibit 73: Gilead: Key customers Exhibit 74: F. Hoffmann-La Roche: Overview Exhibit 75: F. Hoffmann-La Roche: Business segments Exhibit 76: F. Hoffmann-La Roche: Organizational developments Exhibit 77: F. Hoffmann-La Roche: Geographic focus Exhibit 78: F. Hoffmann-La Roche: Segment focus Exhibit 79: F. Hoffmann-La Roche: Key offerings Exhibit 80: F. Hoffmann-La Roche: Key customers Exhibit 81: Vertex Pharmaceuticals: Overview Exhibit 82: Vertex Pharmaceuticals: Business segments Exhibit 83: Vertex Pharmaceuticals: Organizational developments Exhibit 84: Vertex Pharmaceuticals: Geographic focus Exhibit 85: Vertex Pharmaceuticals: Segment focus Exhibit 86: Vertex Pharmaceuticals: Key offerings Exhibit 87: Vertex Pharmaceuticals: Key customers

AbbVie, Gilead, F. Hoffmann-La Roche, and Vertex Pharmaceuticals.